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Acute Symptoms of Mild to Moderate COVID-19 Are 
Highly Heterogeneous Across Individuals and Over Time
Thomas L. Rodebaugh,1,  Madelyn R. Frumkin,1 Angela M. Reiersen,2 Eric J. Lenze,2 Michael S. Avidan,3 J. Philip Miller,4 Jay F. Piccirillo,5 
Charles F. Zorumski,2 and Caline Mattar6
1Department of Psychological and Brain Sciences, Washington University in St Louis, St Louis, Missouri, USA, 2Department of Psychiatry, Washington University School of Medicine (WUSM), 
St Louis, Missouri, USA, 3Department of Anesthesiology, WUSM, St Louis, Missouri, USA, 4Institute for Informatics, Division of Biostatistics, WUSM, St Louis, Missouri, USA, 5Department of 
Otolaryngology, WUSM, St Louis, Missouri, USA, and 6Department of Internal Medicine, Division of Infectious Diseases, WUSM, St Louis, Missouri, USA
Background. The symptoms of coronavirus disease 2019 (COVID-19) appear to be heterogenous, and the typical course of 
these symptoms is unknown. Our objectives were to characterize the common trajectories of COVID-19 symptoms and to assess 
how symptom course predicts other symptom changes as well as clinical deterioration.
Methods. One hundred sixty-two participants with acute COVID-19 responded to surveys up to 31 times for up to 17 days. 
Several statistical methods were used to characterize the temporal dynamics of these symptoms. Because 9 participants showed clin-
ical deterioration, we explored whether these participants showed any differences in symptom profiles.
Results. Trajectories varied greatly between individuals, with many having persistently severe symptoms or developing new 
symptoms several days after being diagnosed. A typical trajectory was for a symptom to improve at a decremental rate, with most 
symptoms still persisting to some degree at the end of the reporting period. The pattern of symptoms over time suggested a fluctuating 
course for many patients. Participants who showed clinical deterioration were more likely to present with higher reports of severity 
of cough and diarrhea.
Conclusions. The course of symptoms during the initial weeks of COVID-19 is highly heterogeneous and is neither predict-
able nor easily characterized using typical survey methods. This has implications for clinical care and early-treatment clinical trials. 
Additional research is needed to determine whether the decelerating improvement pattern seen in our data is related to the phenom-
enon of patients reporting long-term symptoms and whether higher symptoms of diarrhea in early illness presages deterioration.
Keywords.  cough; COVID-19; humans; severe acute respiratory syndrome coronavirus 2; smell; taste.
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The World Health Organization (WHO) and the Centers 
for Disease Control and Prevention (CDC) have described 
common symptoms of the coronavirus disease 2019 (COVID-
19), including fever, dry cough, and difficulty breathing [1, 2]. 
They also report that many people may have few or no symp-
toms despite infection. This characterization is based on studies 
that report cross-sectional or retrospective accounts of symp-
toms from chart review or patient interviews [3–10].
Thus, the temporal dynamics of COVID-19 symptoms are 
unclear. For example, in a patient currently experiencing fever, 
should the patient be concerned about more severe illness if the 
fever seems to resolve but returns a day later? Notably, a recent 
review of long-term COVID-19 symptoms revealed that some 
patients expected a gradual, linear recovery and were troubled 
by symptoms that instead waxed and waned [11]. Moreover, if 
COVID-19 symptoms have highly heterogeneous trajectories, 
this could be a barrier to measuring symptoms as a treatment 
outcome, in that reduction in symptoms on average could mask 
increases in specific symptoms, such that some patients could 
appear to improve (reduction in symptoms overall) while ac-
tually deteriorating (eg, increase in shortness of breath alone).
The aim of the current study is to characterize the temporal 
dynamics of COVID-19 symptoms in a sample of participants 
in a randomized controlled trial testing the medication flu-
voxamine (vs placebo) for early COVID-19 treatment [12]. 
Participants reported on their experience of common COVID-
19 symptoms, as well as blood oxygen level and other clinical 
signs, twice daily for a maximum of 31 times over the course of 
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We used these frequently sampled data to model trajectories 
of the self-reported symptoms. That is, we characterized the 
course of symptoms using latent trajectory models (also called 
latent growth curve models). These models test how to best 
characterize the changes in self-reported symptoms across the 
course of the study in those participants who ever reported that 
symptom. These models are commonly used to study the devel-
opment of symptoms over time [13, 14].
To model trajectories meaningfully, it is essential to obtain se-
quential data in real time, without reliance on retrospection. 
Asking people to recall events results in poor quality data even 
about events that seem highly memorable [15]. With frequently 
sampled data over time, a variety of statistical methods allows the 
researcher to characterize what is generally true in the sample over 
time, as well as to what extent participants vary from this average 
trajectory. Thus, we can determine the ways in which symptoms 
change over time, as well as whether changes in some symptoms 
tend to go together, as might be expected due to some symptoms 
being functionally related (eg, problems with smell and taste).
METHODS
Study Population
Participants were adults living in the community with severe 
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in-
fection confirmed by polymerase chain reaction assay who 
were currently symptomatic with symptom onset <7 days be-
fore beginning survey responses. Exclusion criteria included 
COVID-19 severe enough to require hospitalization or meeting 
the study’s primary end point for clinical deterioration at 
baseline (ie, oxygen saturation of <92% on room air), med-
ical comorbidities including severe underlying lung disease 
(chronic obstructive pulmonary disease or home oxygen, in-
terstitial lung disease, pulmonary hypertension), decompen-
sated cirrhosis, congestive heart failure (stage 3 or 4), and being 
immunocompromised (solid organ transplant, bone marrow 
transplant recipient, AIDS, on biological immunologic medi-
cations or high-dose steroids [>20 mg of prednisone per day]).
The clinical trial’s primary outcome measure was clinical 
deterioration, defined by meeting both of the following: (1) 
presence of dyspnea (ie, shortness of breath) and/or hospital-
ization for shortness of breath or pneumonia plus (2) decrease 
in oxygen saturation (<92%) on room air and/or supple-
mental oxygen requirement in order to keep oxygen saturation 
≥92%. Participants typically stopped completing surveys on 
their symptoms once they met the primary outcome criteria. 
However, data are available from 1 participant who experienced 
moderate deterioration halfway through the trial and continued 
to provide data after deterioration. Notably, because we in-
cluded all participants who provided any symptom survey data, 
we report on an additional 10 participants not included in the 
parent study [12]; these subjects were excluded from the parent 
study because they either could not be confirmed to have taken 
the study drug (n = 7) or were deteriorated at baseline (n = 3).
Patient Consent Statement
The study was approved by Washington University’s Institutional 
Review Board before initiating any recruitment, and all partici-
pants provided informed consent via an e-consent or written 
consent.
Survey
Data collection occurred via REDCap surveys sent to parti-
cipants via email, with telephone-based data collection as a 
backup to ensure that individuals without internet access were 
able to participate. The data collection used an ecological mo-
mentary assessment (EMA) framework. EMA (vs standard data 
collection methods) is thought to limit biased responding in 
participants due to retrospection because in EMA participants 
are asked about their current experience [16]. The surveys re-
corded COVID-19 symptoms, oxygen saturation, vital signs, 
and medication adherence. Participants completed a baseline 
survey before starting the study medication, followed by surveys 
approximately twice a day for 15  days after starting the study 
drug; occasional delayed responding or technical errors led to 
a maximum of 17 days. At each survey, participants were asked 
whether they were experiencing a symptom at all. When they in-
dicated “no,” this was coded as a value of 0. When they reported 
“yes,” they were then asked to rate the perceived severity of the 
symptom on a scale from 1 to 10. The symptoms rated included 
perceived fever, cough, shortness of breath, fatigue or weakness, 
chills, nausea, body aches, diarrhea, loss of appetite, difficulty 
with sense of smell, and difficulty with sense of taste.
Statistical Analysis
Analyses were conducted in Mplus [17], with visualizations 
produced in R. Because these analyses were not preregistered, 
we recommend considering them primarily descriptive and ex-
ploratory. Results are reported for the entire group of partici-
pants without reference to randomized controlled trial (RCT) 
group because there were no clear differences between groups 
on latent trajectory outcomes (the same 30 tests were conducted 
as reported below for demographic variables, yet the lowest P 
value was .015, whereas we considered .01 significant due to the 
large number of tests). Additional details on analyses and rele-
vant statistical output are available in the Supplementary Data 
as well as at https://osf.io/t8frj/.
RESULTS
Participant Characteristics
In total 162 participants completed at least some EMA sur-
veys (n = 162; median surveys answered, 23; median days cov-
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reported were mostly White (70%, n  =  106), although many 
participants reported that they were Black (25%, n = 38), with 
an average age (SD) of 45.80 (13.04). The sample was primarily 
female, as judged by the number reporting being assigned fe-
male sex at birth (69%, n = 109).
Symptom Frequency and Severity Across and Within Patients Over Time
The most common rating for all symptoms was 0, or not present 
(Supplementary Table 1; Supplementary Figure 1). Figure 1, 
which depicts raw data for all symptoms for a random set of 
participants, demonstrates that the frequent ratings of 0 oc-
curred in a number of patterns, including symptoms never 
occurring, occurring and then resolving, starting in the middle 
of the reporting period, and fluctuating during some portion of 
the reporting period. The frequent “saw tooth” patterns seen in 
Figure 1 suggest symptoms waxing and waning. An expanded 
version of this figure is available in the Supplementary Figure 2. 
Heterogeneity of Symptom Trajectories
To handle the frequent instance of 0s in the data, before pro-
ceeding with further analysis we (1) restricted further analysis 
to participants who ever had that symptom and (2) consolidated 
symptom reports to 5 time points (Times 0 through 4). This 
procedure had the effect of “smoothing out” the sawtooth pat-
tern present for many participants, allowing analysis of overall 
tendencies over time.
We examined typical trajectories using latent trajectory mod-
eling. These models focus on slopes and intercepts as a way to 
characterize the course of symptoms across the whole sample. 
The intercept refers to the participant’s estimated level of the 
symptom at Time 0 (ie, during the first 3 days of the study). For 
participants with only random fluctuations or a stable level of a 
symptom, the intercept would be enough to characterize their 
data, while the existence of a slope denotes that there are system-
atic changes in the symptom. A linear slope indicates a tendency 
up or down. A quadratic slope indicates some curve to the line’s 
shape. A cubic slope indicates a second curvature of the line. The 
modeling allows us to determine whether the data are well char-
acterized by the intercept and 1 or more slopes, as well as how 
many slopes are required to characterize the data of participants 
overall. The modeling also allows us to determine whether and 
how individual participants significantly vary from the average 
group trajectory. For example, the model might show that the 
mean slope is negative, indicating resolution of a symptom, but 
with significant variance, indicating that some participants are 
better characterized by an upward slope of symptoms.
Of the symptoms, only nausea was not reasonably well char-
acterized by a latent trajectory model. As shown in Table 1, all 
other symptoms were best characterized by at least 1 curvilinear 
slope in addition to a linear slope, typically showing a decrease 
but with deceleration. Because we only analyzed those partici-
pants who reported the symptom at some point, the number for 
each model (vs 162 who supplied any EMA) shows how com-
monly the symptom was reported. The most common symp-
toms were fatigue, fever, reduced appetite, and problems with 
sense of taste. The linear slopes all had negative means. Thus, 
participants on average tended to show reductions in symptoms 
over time, but the significant variance of most of the slopes indi-
cates that many participants showed increases in symptoms. As 
a reminder, there was no indication that participants differed in 
these trajectories based on treatment group.
On the average, judging from the linear slope values, par-
ticipants recovered the quickest from aches and low appetite 
and most slowly from cough and difficulty breathing. With the 
Table 1. Summary of Latent Trajectory Models
Symptom
Participants in  
Analysis
Intercept Mean  
(Variance)
Linear Slope Mean  
(Variance)
Quadratic Slope Mean  
(Variance)
Cubic Slope Mean  
(Variance)
Ache2 120 3.80** (6.45**) –1.50** (2.10*) 0.20** (0.07*)  
Appetite1 121 3.85** (4.45**) –1.54** (0.99*) 0.18** (0.04*)  
Breath2 89 2.11** (2.86**) –0.37* (1.33*) 0.02 (0.06*)  
Chill1 74 2.25** (3.63*) –1.13** (1.54*) 0.15** (0.04)  
Cough3 129 2.86** (4.65**) –0.51** (0.94*) 0.01 (0.05*)  
Diarrhea2 100 1.66** (1.68*) –0.66* (0.00a) 0.08* (0.01)  
Fatigue3 144 4.26** (5.34**) –1.35** (1.61**) 0.15** (0.06**)  
Fever3 72 2.26** (6.06**) –1.15** (2.84**) 0.16** (0.08*)  
Smell1 112 5.80** (5.79**) –1.32** (4.20*) 0.10 (0.16*)  
Taste3 119 5.06** (9.20**) –1.05* (10.67**) –0.07 (1.89**) 0.03 (0.04**)
Latent trajectory models were conducted on participants (n = 162) who ever reported the symptom. The intercept, linear, and quadratic slopes are then given. Intercepts indicate where 
participants start, on average, whereas linear slope indicates the general tendency up or down. Additional slopes indicate the extent to which symptom courses frequently reversed, slowed, 
or accelerated. Unstandardized estimates are given because these are directly relevant to the response scale of 0 (not at all) to 10 (most severe). Statistically significant slopes indicate 
that participants showed a group tendency overall. Significant variances indicate that participants meaningfully differed in this tendency. Thus, for example, despite the linear slopes being 
negative, at least 1 participant had a positive slope where the variance was statistically significant.
*P < .05; **P < .001.
1,2,3Indicates number of fit indices showing good to excellent fit. When the number is higher, we can be more certain that the model describes the overall sample well. Further information 
on fit is available in individual outputs in the Supplementary Data.
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exception of problems with sense of taste, all other symptoms 
had a second quadratic term that was positive, which indicates 
that although their symptoms went down, the rate at which they 
dropped began to slow. Thus, the most typical course was an ini-
tially rapid recovery followed by some plateauing, or a pattern of 
decelerating improvement. Most symptoms had significant var-
iance in both the linear and quadratic slope, which means that 
the curve could also move in a different direction for some par-
ticipants. For example, some participants increased in symptoms 
and then decreased, whereas others had stable levels of symptoms 
or had increased symptoms that were maintained across the rest 
of the reporting period. The picture is even more complicated 
for taste, which had an additional cubic slope. This symptom 
thus showed at least 2 inflection points for many participants, as 
would be true if the symptom went up, down, and then up again.
Figure 2 displays illustrative curves for each symptom. These 
figures display the most typical (mean) course, alongside the 
typical course of (1) participants whose symptoms reduced rap-
idly, as well as (2) those whose symptoms either reduced more 
slowly or were exacerbated. In the latter 2 cases, the 10 parti-
cipants with the most extreme linear slopes had their param-
eters averaged to depict a typical rapidly improving and slowly 
improving course (with the exception of diarrhea, for which 
the most extreme quadratic courses were averaged because the 
linear slope had no variance). Finally, the single participant 
who deteriorated according to study criteria yet also provided 
a full set of EMA data is also presented. This participant ex-
perienced moderate deterioration and visited the emergency 
room midway through the reporting period. Examining this 
participant’s raw data revealed no obvious signs of the deterio-
ration aside from 3 elevated ratings of shortness of breath (a 5 or 
6 out of 10) that occurred around this period, with these ratings 
surrounded by ratings of 0.
A further depiction of the wide variety of slopes is provided 
in Figure 3. Here we depict trajectories for the 5 symptoms with 
the best-fitting models. On the left, we see the average course 
of all of these symptoms is an improvement in mild symptoms 















































Chills Cough Diarrhea Fatigue Fever Nausea Smell Taste
Figure 1. Up to a 17-day course (median, 16) of symptoms for 10 randomly selected participants on a per-symptom basis. Each row includes data for 1 participant. Time 
points are ~12 hours apart on up to 17 days. Note the “saw tooth” pattern for many participants, indicating symptoms that wax and wane. An expanded version of this figure 
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show us that these average trajectories vary significantly across 
individuals, with symptoms rising and falling at different rates 
across people. An expanded version of this figure is available in 
the Supplementary Data.
How Symptoms Change Together Over Time
Table 2 shows the correlations among linear slopes. Each 
person’s linear slope tells us to what extent their symptoms gen-
erally tend to go up or down over time. The correlation between 
these slopes tells us whether we should expect that participants 
have symptoms that go together as they improve or worsen. 
Some pairs stood out with particularly strong correlations. 
These include problems with taste and smell, cough and trouble 
breathing, chills and fever, and, to a lesser extent, ache and fa-
tigue. Thus, for example, we would expect that for a participant 
whose symptoms included both cough and trouble breathing 
these symptoms would tend to go up or down together over 
time. In contrast, for a participant with fever and trouble 
breathing, we would have no reason to expect that a reduction 
in fever should necessarily go along with improved breathing, 
because the correlation is small and negative.
Symptom Dynamics, Demographics, and Clinical Deterioration
Most participants who deteriorated did so in the first several 
days and stopped providing EMA data. Thus, most of the 9 
participants who deteriorated provided data only for Time 
0 for the trajectories presented. Accordingly, we examined 
differences between the 9 participants who deteriorated (ie, 
developed dyspnea and hypoxia) and the rest of the sample 
only in the intercepts (the only meaningful trajectory in-
formation for participants who only reported during Time 
0). Given the small sample of participants who deterior-
ated, Mann-Whitney U tests were conducted. Two effects 
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Ache Appetite Breath Chills Cough
Diarrhea Fatigue Fever Smell Taste
Figure 2. Representative courses of coronavirus disease 2019 symptoms across up to 17 days (median, 16 days). Each time point represents the average of 3 days, except 
that Time 4 included up to 5 days, but more typically 3 or 4. The Average line represents the average trajectory across the entire data set. The Rapid improvement and Slower 
improvement lines are the average for the 10 participants, with the strongest linear slope in the improving and worsening directions. For diarrhea, the quadratic slope was 
used as the linear slope had no variance. A worsening linear slope did not always translate to symptoms being aggravated overall because trajectories were curvilinear. 
Slower improvement lines are not depicted for appetite or chills because too few participants experienced worsening in this symptom as indexed by the linear slope. The 
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number of tests conducted in this analysis: Participants who 
deteriorated were far more likely to have an elevated inter-
cept (ie, higher initial levels) for both cough and diarrhea 
(all P = .002).
We also examined demographic variables to see if symptom 
dynamics differed, adopting a P of .01 to balance multiple 
testing against discovery of potentially important findings. Men 












































































Figure 3. On the left, the average course of 5 common symptoms across up to 17 days (median number of days, 16). On the right, 9 randomly selected participants (of those 
who had all 5 symptoms) and their individual trajectories. Note that because the model fits a curve to data points, the curve can transiently go above the response scale. An 
expanded version of this figure is available in the Supplementary Data.
Table 2. Partial Correlations Between Pairs of Linear Slopes Controlling for Intercepts With Number of Participants for Each Comparison
Ache Appetite Breath Chill Cough Fatigue Fever Smell Taste
Ache  97 75 68 100 114 63 90 93
Appetite 0.26*  73 65 100 115 61 89 97
Breath 0.39** 0.09  54 82 85 47 68 76
Chill 0.33** –0.01 0.38**  62 72 50 50 61
Cough 0.36** 0.13 0.68** 0.23  118 63 93 98
Fatigue 0.51** 0.44** 0.46** 0.31** 0.33**  69 104 111
Fever 0.06 0.10 –0.04 0.65** 0.09 0.15  52 58
Smell 0.23* 0.30** 0.04 0.00 0.18 0.32** –0.11  104
Taste 0.23* 0.35** 0.07 0.19 0.23* 0.31** 0.09 0.74**  
No. for each comparison is on the top diagonal. Positive correlations indicate that symptoms tend to go either or up or down together. Negative correlations indicate that the symptoms 
diverge in trajectories (as 1 goes up, the other goes down). Thus, problems with smell are very likely to resolve along with problems with taste. Diarrhea is not included in these analyses 
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Black participants had a significantly higher intercept of chill 
and cough (all P  <  .007), suggesting more severe symptoms 
at the start of the study. No other slopes or intercepts showed 
clearly significant differences. Body mass index (BMI) did not 
correlate significantly with any intercepts or slopes. Thus, there 
were few signs that demographic variables were related to the 
course of COVID-19 symptoms.
DISCUSSION
Our study characterizes the course of COVID-19 among 
community-dwelling patients who are recovering at home. 
This information is important because it informs clinicians, 
patients, and researchers about the high degree of heteroge-
neity, both between and within patients. We made the fol-
lowing 4 major observations: First, the COVID-19 symptom 
course is highly heterogenous. Second, early symptoms re-
lated to participant demographics and clinical deterioration. 
Third, symptoms often showed a pattern of decelerating im-
provement. Fourth, some symptoms are likely to improve 
in tandem, whereas others are not. We discuss each of these 
points further below.
The overall picture is of symptoms reducing for most partici-
pants, but often with a slowing of this reduction, often further 
complicated by waxing and waning of symptoms (eg, across 
12-hour periods). Further, problems with the sense of taste were 
characterized by additional curvilinearity, reflecting increased 
volatility. As a notable example, the participant who clinically 
deteriorated (developed dyspnea and hypoxia) did this in spite 
of symptoms showing average or rapidly improving course in 
some respects. Although this is a report of only a single par-
ticipant who experienced moderate deterioration, it stands as 
a warning that deterioration in COVID-19 can be rapid and 
unpredictable.
We found no evidence that symptom dynamics varied mean-
ingfully across the treatment groups from the parent study, nor 
any association with BMI. However, participants who deteri-
orated were more likely to have initially high levels of cough 
and diarrhea. This finding should be taken as exploratory and 
requiring confirmatory tests of whether higher levels of these 
symptoms in the initial days of illness might presage clinical de-
terioration, especially because 3 of our deteriorated participants 
were deteriorated at baseline. Importantly, our more global 
findings indicate that the time frame of assessment might be 
crucial. Our finding is that participants with higher self-report 
of cough and diarrhea near the beginning of their illness were 
more likely to experience deterioration at some point. Because 
symptom courses often wax and wane, asking participants if 
they ever experienced that symptom or experienced it later in 
the illness would not necessarily yield the same result. However, 
at least 1 report has found that diarrhea presaged clinical de-
terioration [18]. We expect that our finding regarding cough 
might simply reflect the fact that most of those who deterior-
ated did so early in the reporting period, but the possibility that 
severity of cough actually predicts deterioration seems worth 
investigating.
Our findings indicate that patients and health care providers 
can expect a variety of symptom courses, including the devel-
opment of additional symptoms and a gradual and potentially 
stalling decline of some symptoms. The latter finding is con-
sistent with another study showing that a minority of partici-
pants continue to experience symptoms, particularly cough, 
fatigue, and shortness of breath [6]. In our results, cough and 
shortness of breath showed the smallest slope downward on 
average, suggesting, in combination with previous results, that 
these symptoms in particular are likely to be prolonged for 
many patients.
Whether the decelerating improvement pattern is unique 
to COVID-19 is difficult to determine because few studies 
have examined other common infectious diseases in regard to 
common trajectories of symptoms. However, a report focusing 
on the development of a symptom measure for influenza re-
ported the average course of several symptoms [19]. Although 
challenging to compare directly due to differences in method-
ology, our results seem to suggest (1) a longer course for sig-
nificant symptoms of COVID-19 and (2) a greater deceleration 
in improvement across the second week. That is, for influenza 
symptoms, rapid recovery over the first 4 days (Time 0 to Time 1 
in our analysis) was followed by a more gradual, approximately 
linear slope for the remainder of the days assessed. Our partici-
pants experienced more gradual initial improvement, followed, 
most commonly, by a greater deceleration of improvement.
Judging from correlated slopes, some pairs of symptoms are 
likely to reduce in tandem. The strongest candidate for such a 
pairing is problems with smell and taste, which should be ex-
pected given the functional connection between the 2 senses. 
Similarly, cough and shortness of breath, fever and chills, and, 
to a lesser extent, ache and fatigue are all pairs that show a ten-
dency to decline over time together.
Limitations
The results of the study should be interpreted in light of its limi-
tations. Patients were enrolled after diagnosis, which could have 
been up to 7 days after experiencing symptoms, and even longer 
after infection. This fact could explain some of the wide variety 
of trajectories, but not the observed waxing and waning or 
stalled improvement. Data were drawn from an RCT, with lim-
ited diversity in patient population, conducted in 1 Midwestern 
metropolitan area, during the initial 7 months of the COVID-
19 outbreak. It is unclear to what extent we should expect prev-
alent symptoms of COVID-19 or their course to vary by virus 
variant, demographics, community, or even country. It is pos-
sible that although asking participants first whether they had a 
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have inclined participants to answer “no” even if a symptom 
was present in a mild form. Participants provided self-report 
of symptoms, which especially must be kept in mind when at-
tempting to apply results to objective conditions. For example, 
1 report found that a significant proportion of participants with 
COVID-19 reporting olfactory dysfunction did not meet cri-
teria upon evaluation [20]. Nevertheless, self-reported symp-
toms of problems with smell and taste have emerged as 2 of the 
best predictors of COVID-19 status [21, 22].
CONCLUSIONS
In conclusion, COVID-19 is a heterogeneous illness in terms 
of subjective symptoms and course. When patients experience 
a given symptom, it may fluctuate but will typically follow a 
gradual improvement over the course of 2 weeks or more. Many 
patients, however, will develop new symptoms during the same 
course, and many symptoms may take considerably beyond a 
2-week window to resolve completely. This tendency toward 
slowly improving symptoms may be related to the increasing 
reports of a more chronic form of the disease in certain popu-
lations [6, 8, 11]. It is important to warn patients, and clinicians 
caring for them, not to expect a linear decrease in all symptoms; 
some may be intermittent or get worse before they get better. 
Future studies following a cohort of patients with COVID-19 
symptoms over a longer period of time could be useful in de-
termining how, if at all, acute symptom presentation relates to 
chronic symptom experiences.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online as well as at https://osf.io/t8frj/. Consisting of data provided by the 
authors to benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or comments should 
be addressed to the corresponding author.
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